Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | MGLL | Q99685 | 9/20 | 0.86 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.86 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1720669 | 0.94 | MEN1 (0.88) | MEN1KMT2AMGLLHSD11B1ALDH1A1 | |
| SCHEMBL6209947 | 0.93 | HSD11B1 (1.00) | MEN1KMT2AMGLLHSD11B1ALDH1A1 | |
| SCHEMBL6211115 | 0.90 | MEN1 (0.81) | MEN1KMT2AMGLLHSD11B1ALDH1A1 | |
| SCHEMBL6257275 | 0.90 | MEN1 (0.81) | MEN1KMT2AMGLLHSD11B1ALDH1A1 | |
| SCHEMBL27892703 | 0.88 | KMT2A (0.79) | MEN1KMT2AMGLLHSD11B1ALDH1A1 | |
| SCHEMBL29448588 | 0.87 | KMT2A (0.77) | MEN1KMT2AMGLLHSD11B1ALDH1A1 | |
| SCHEMBL6747296 | 0.87 | KMT2A (0.77) | MEN1KMT2AMGLLHSD11B1ALDH1A1 | |
| SCHEMBL16446847 | 0.87 | KMT2A (0.77) | MEN1KMT2AMGLLHSD11B1ALDH1A1 | |
| SCHEMBL14687336 | 0.85 | KMT2A (0.73) | MEN1KMT2AMGLLHSD11B1ALDH1A1 | |
| SCHEMBL12302035 | 0.85 | KMT2A (0.74) | MEN1KMT2AMGLLHSD11B1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | claimed |
| EP-1556349-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | Astrazeneca AB (SE) | 2005-07-27 | — | — | EP | claimed |
| WO-2004033427-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | WO | claimed |
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| EP-1556349-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | Astrazeneca AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004033427-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | HSD11B1, HSD3B1, P4HA1 | MEN1 2970/4885KMT2A 1395/4885MGLL 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.